NICE the UK HMO, Published Guidance on Denosumab for the Treatment of Therapy-Induced Bone Loss in Non-Metastatic Prostate Cancer (terminated appraisal)

Full Text Here

NICE is unable to recommend the use in the NHS of denosumab for the treatment of therapy-induced bone loss in people with non-metastatic prostate cancer because no evidence submission was received from the manufacturer or sponsor of the technology.

The manufacturer of denosumab (Amgen) was invited to submit evidence for this single technology appraisal of denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer.
In August 2009, Amgen informed NICE that it would not be making an evidence submission. Amgen stated that there was a high volume of upcoming NICE technology appraisals of Amgen products and in order to ensure best overall use of resources, it has decided to focus its resources on other topics.
NICE has therefore terminated this single technology appraisal.

For a Market Access and Health Economics Expert Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”